MedTrace Logo

De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

NCT05808192 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2023-04-11

No results posted yet for this study

Summary

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

Conditions

  • Single Transplant
  • 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

Interventions

DRUG

Immunosuppressive

compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Sponsors & Collaborators

  • University of Rome Tor Vergata

    lead OTHER

Eligibility

Min Age
49 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-02-01
Completion
2022-05-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05808192 on ClinicalTrials.gov